Post-Remission AML: To Transplant or Not? Navigating Complex Clinical Decisions

This session explores the evolving decision-making landscape in post-remission acute myeloid leukemia (AML), focusing on the critical question of whether to proceed with allogeneic hematopoietic cell transplantation. Dr. Pinkal Desai will examine contemporary risk stratification strategies integrating measurable residual disease (MRD), genomic profiling, and patient-specific factors to refine transplant candidacy. Recent data from major hematology meetings highlighting the prognostic impact of MRD status, the role of novel maintenance therapies (including FLT3 and IDH inhibitors), and outcomes with reduced-intensity conditioning will be discussed. The session will also address emerging approaches for older or unfit patients and the influence of targeted therapies on delaying or obviating transplant. Through case-based discussion, participants will gain practical insights into balancing relapse risk, treatment-related morbidity, and patient preferences in complex clinical scenarios.